Cantor Fitzgerald Brokers Boost Earnings Estimates for ESPR

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Equities research analysts at Cantor Fitzgerald raised their FY2025 earnings per share estimates for shares of Esperion Therapeutics in a research note issued on Wednesday, March 12th. Cantor Fitzgerald analyst K. Kluska now forecasts that the biopharmaceutical company will post earnings per share of $0.12 for the year, up from their prior forecast of $0.05. Cantor Fitzgerald currently has a “Overweight” rating and a $8.00 target price on the stock. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.29) per share.

Several other research analysts have also recently weighed in on ESPR. JMP Securities restated a “market outperform” rating and set a $4.00 target price (down from $7.00) on shares of Esperion Therapeutics in a report on Tuesday, February 11th. The Goldman Sachs Group began coverage on Esperion Therapeutics in a report on Wednesday, December 18th. They set a “neutral” rating and a $4.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price target on shares of Esperion Therapeutics in a research report on Tuesday, March 4th. Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 price target on shares of Esperion Therapeutics in a research report on Friday, December 13th. Finally, StockNews.com lowered shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, Esperion Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $6.75.

Esperion Therapeutics Stock Performance

ESPR stock opened at $1.50 on Friday. Esperion Therapeutics has a 12-month low of $1.47 and a 12-month high of $3.94. The stock has a market cap of $296.77 million, a price-to-earnings ratio of -2.34 and a beta of 1.04. The business’s 50-day moving average is $1.89 and its 200 day moving average is $2.07.

Hedge Funds Weigh In On Esperion Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of ESPR. Mackenzie Financial Corp raised its holdings in shares of Esperion Therapeutics by 116.1% in the fourth quarter. Mackenzie Financial Corp now owns 143,252 shares of the biopharmaceutical company’s stock valued at $315,000 after buying an additional 76,965 shares during the last quarter. Two Sigma Advisers LP raised its holdings in shares of Esperion Therapeutics by 0.4% in the fourth quarter. Two Sigma Advisers LP now owns 3,616,200 shares of the biopharmaceutical company’s stock valued at $7,956,000 after buying an additional 16,100 shares during the last quarter. Rafferty Asset Management LLC purchased a new position in Esperion Therapeutics during the fourth quarter worth about $82,000. ProShare Advisors LLC increased its holdings in Esperion Therapeutics by 75.2% in the fourth quarter. ProShare Advisors LLC now owns 62,549 shares of the biopharmaceutical company’s stock valued at $138,000 after buying an additional 26,843 shares in the last quarter. Finally, Nuveen Asset Management LLC increased its holdings in Esperion Therapeutics by 48.6% in the fourth quarter. Nuveen Asset Management LLC now owns 3,119,253 shares of the biopharmaceutical company’s stock valued at $6,862,000 after buying an additional 1,020,243 shares in the last quarter. Institutional investors and hedge funds own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.